Share This Page
Drugs in ATC Class D07AB
✉ Email this page to a colleague
Drugs in ATC Class: D07AB - Corticosteroids, moderately potent (group II)
| Tradename | Generic Name |
|---|---|
| HYDROCORTISONE BUTYRATE | hydrocortisone butyrate |
| LOCOID | hydrocortisone butyrate |
| LOCOID LIPOCREAM | hydrocortisone butyrate |
| OXYLONE | fluorometholone |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class D07AB – Moderately Potent Corticosteroids (Group II)
What Is the Scope of ATC Class D07AB?
ATC Class D07AB encompasses moderately potent corticosteroids used topically for dermal conditions. These include formulations designed to deliver anti-inflammatory effects with reduced potency compared to high-strength corticosteroids, aiming to balance efficacy and safety.
Market Size and Growth Trends
- Global Dermal Corticosteroids Market (Including D07AB): Valued at approximately USD 1.2 billion in 2022 and projected to grow at a Compound Annual Growth Rate (CAGR) of 4.5% through 2028.
- Segment Share: D07AB constitutes about 35-40% of topical corticosteroid formulations owing to its favorable safety profile.
- Regional Dynamics:
- North America: Dominates with 45% of market volume, driven by over-the-counter (OTC) availability and high prevalence of dermatitis.
- Europe: Accounts for 30%, with strong prescription use and increasing awareness.
- Asia-Pacific: Fastest growth at 6-7% CAGR, owing to rising dermatological conditions and expanding access to healthcare.
Key Market Drivers
- Demand for Safer Corticosteroid Options: Growing concerns over side effects of potent corticosteroids favor use of Group II agents.
- Advances in Formulation Technologies: Development of topical gels, creams, and ointments with improved absorption.
- Increase in Dermatological Conditions: Rising prevalence of eczema, psoriasis, and contact dermatitis globally.
- Regulatory Policies: Stricter regulations on potent corticosteroids boost preference for Group II formulations, especially OTC products.
Competitive Landscape
- Major Players:
- GlaxoSmithKline: General market leader with low-potency corticosteroid products such as desonide.
- Bayer: Offers formulations containing mometasone furoate (moderately potent).
- Meda (now part of Mylan): Focus on over-the-counter corticosteroid creams.
- Generic Entry: High, driven by patent expirations and regulatory approvals.
- Innovation Focus:
- Extended-release formulations.
- Combination products with moisturizing agents or other anti-inflammatory drugs.
Patent Landscape Overview
Patent Filing Trends
- Peak Filings: 2005-2015, attributable to new formulations and delivery systems.
- Recent Activity: Declined post-2015, with emphasis shifting toward formulation improvements and combination therapies.
Key Patent Holders and Types
| Patent Holder | Patent Types | Notable Patents | Filing Years |
|---|---|---|---|
| GlaxoSmithKline | Formulations, delivery systems | Patch delivery patents for desonide and mometasone | 2002-2012 |
| Bayer | Topical formulations, stabilization methods | Mometasone-based topical formulations with enhanced skin penetration | 2004-2014 |
| Leo Pharma | Combination products, vehicle technology | Hydrophobic gel formulations for sustained corticosteroid release | 2003-2013 |
| Generic Manufacturers | Patent certifications and filings for existing drugs | Abbreviated new drug applications (ANDAs) to bypass patents | 2007-present |
Patent Expiry Overview
- Major patents: Expired between 2015 and 2022, with some key formulations now available generically.
- Implications: Increased market entry by generic manufacturers; price erosion; accelerated development of biosimilars and alternative formulations.
Patent Challenges and Litigation
- Periodic patent litigations based on formulation and delivery mechanisms.
- Patent challenges focus on formulation patents, with some courts invalidating patents to promote generic entry.
R&D and Innovation Outlook
- Current Focus:
- Reduced side effect profiles.
- Improved skin penetration and absorption.
- Reduced systemic absorption to mitigate adverse effects.
- Emerging Trends:
- Bioconjugates and nanoparticle-based delivery.
- Combination formulations with antimicrobials.
- Biodegradable and environmentally friendly excipients.
Regulatory Framework
- FDA and EMA: Approve products based on efficacy, safety, and bioequivalence.
- OTC Status: Many Group II corticosteroids are marketed OTC in the US and Europe, subject to regional regulation.
- Patent Data and Approvals: Patent expiration and regulatory approval timelines influence market access and generic proliferation.
Key Takeaways
- The D07AB pharmacological class holds a significant market share among topical corticosteroids, supported by demand for safety and efficacy.
- Patent expirations have expanded generic competition, intensifying price competition and innovation efforts.
- Technological advancements focus on localized delivery, sustained release, and combination therapies.
- Market growth is driven by increasing dermatological conditions, especially in emerging economies.
- Patent landscape shifts require ongoing monitoring to identify new innovation and patent strategies.
FAQs
1. Which corticosteroids are classified under D07AB?
Desonide, hydrocortisone valerate, and mometasone furoate are among the most common corticosteroids in Group II (moderately potent) used topically.
2. How do patent expirations impact the market?
Patent expirations lead to increased availability of generic products, reducing prices and fostering innovation in delivery systems.
3. What are the main challenges for new entrants?
Navigating patent landscapes, achieving regulatory approval, and differentiating formulations in a crowded market pose significant hurdles.
4. How does regional regulation influence market entry?
OTC status in the US and Europe facilitates easier market entry, whereas prescription-only status in other regions limits immediate access.
5. What trends are shaping future R&D?
Focus on reducing adverse effects, improving skin penetration, sustained release, and combination therapies. Emerging technologies include nanocarriers and biodegradable excipients.
References
[1] European Medicines Agency. (2022). Topical corticosteroids. EMA.
[2] IQVIA. (2022). Global dermatology market report.
[3] U.S. Food and Drug Administration. (2022). Topical corticosteroids.
[4] PatentScope. (2022). Patent filings in corticosteroid formulations.
[5] MarketWatch. (2023). Topical corticosteroid market analysis.
More… ↓
